BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report

BACKGROUND: Mutations in the human breast cancer susceptibility gene 2 (breast cancer 2, BRCA2) increase the risk of breast, ovarian and other cancers. Olaparib, an oral poly[adenosine diphosphate (ADP)–ribose] polymerase (PARP) inhibitor, is usually prescribed to treat BRCA mutated tumors, especial...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhujun, Wang, Kang, Zhao, Lintao, Gong, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228719/
https://www.ncbi.nlm.nih.gov/pubmed/37260982
http://dx.doi.org/10.3389/fonc.2023.1190100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228719/
https://www.ncbi.nlm.nih.gov/pubmed/37260982
http://dx.doi.org/10.3389/fonc.2023.1190100

Ejemplares similares